| Literature DB >> 25609310 |
Jeremy A Kroemer1, Bryony C Bonning2, Robert L Harrison3.
Abstract
Since the development of methods for inserting and expressing genes in baculoviruses, a line of research has focused on developing recombinant baculoviruses that express insecticidal peptides and proteins. These recombinant viruses have been engineered with the goal of improving their pesticidal potential by shortening the time required for infection to kill or incapacitate insect pests and reducing the quantity of crop damage as a consequence. A wide variety of neurotoxic peptides, proteins that regulate insect physiology, degradative enzymes, and other potentially insecticidal proteins have been evaluated for their capacity to reduce the survival time of baculovirus-infected lepidopteran host larvae. Researchers have investigated the factors involved in the efficient expression and delivery of baculovirus-encoded insecticidal peptides and proteins, with much effort dedicated to identifying ideal promoters for driving transcription and signal peptides that mediate secretion of the expressed target protein. Other factors, particularly translational efficiency of transcripts derived from recombinant insecticidal genes and post-translational folding and processing of insecticidal proteins, remain relatively unexplored. The discovery of RNA interference as a gene-specific regulation mechanism offers a new approach for improvement of baculovirus biopesticidal efficacy through genetic modification.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25609310 PMCID: PMC4306846 DOI: 10.3390/v7010422
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Representation of the baculovirus life cycle.
Recombinant baculoviruses that express peptide neurotoxins.
| Recombinant Baculovirus | Insecticidal Peptide | Parental Virus/Host Species 1 | Promoter | Signal Peptide | Improvement | Reference 3 |
|---|---|---|---|---|---|---|
| vBeIt-1 | BeIT (scorpion) | AcMNPV/ | None | No larval paralysis | [ | |
| vBeIt-2 | BeIT | AcMNPV/ | Human β-interferon | No larval paralysis | [ | |
| vBeIt-3 | Polyhedrin-BeIT fusion | AcMNPV/ | None | No larval paralysis | [ | |
| BmAaIT | AaIT(scorpion) | BmNPV/ | bombyxin | 40% | [ | |
| AcUW2(B).AaIT [
| AaIT | AcMNPV/ | bombyxin | 12%–50% ( | [ | |
| AcST-1 | AaIT | AcMNPV/ | None | No neurotoxin secretion from infected cells | [ | |
| AcST-3 | AaIT | AcMNPV/ | AcMNPV GP67 | 24%, 25% | [ | |
| vEV-Tox34 | TxP-I (mite) | AcMNPV/ | native | Not estimated | [ | |
| vETL-Tox34 | TxP-I | AcMNPV/ | ETL (AcMNPV ORF | native | Not estimated | [ |
| vCappolh-Tox34 | TxP-I | AcMNPV/ | native | Not estimated | [ | |
| vSp-tox34 | TxP-I | AcMNPV/ | synXIV | native | 33%–59% ( | [ |
| vSp-tox21A | AcMNPV/ | synXIV | native | 34%; 49% | [ | |
| vEV-HA5f10 | AcMNPV/ | native | No larval paralysis or other effect | [ | ||
| vEV-HA5f17 | AcMNPV/ | native | No larval paralysis or other effect | [ | ||
| AcLα22 (vAcLqαIT) | LqhαIT (scorpion) | AcMNPV/ | native | 27%–41% ( | [ | |
| AcNPV/RH1 | AaIT | AcMNPV/ | bombyxin | 31% | [ | |
| vSp-tox34m | TxP-I | AcMNPV/ | synXIV | modified native | 44%; 54% | [ |
| vSp-BSigtox34 | TxP-I | AcMNPV/ | synXIV | 26% | [ | |
| vSp-tox21A/tox34 | TxP-I | AcMNPV/ | synXIV | 36% | [ | |
| vSp-DCtox34 | TxP-I | AcMNPV/ | synXIV | 47% | [ | |
| vpHSP70tox34 | TxP-I | AcMNPV/ | native | 41%; 46% | [ | |
| vDA26tox34 | TxP-I | AcMNPV/ | DA26 (AcMNPV ORF | native | 28%; 39% | [ |
| vp6.9tox34 | TxP-I | AcMNPV/ | native | 56%–59% ( | [ | |
| vp6.9tox34m | TxP-I | AcMNPV/ | modified native | 53%; 54% | [ | |
| TnNPV-AaIT (clones 1–4) | AaIT | “TnNPV”/ | synXIV | AcMNPV GP67 | 20%–43% | [ |
| vMAg4p+ | μ-Aga-IV (spider) | AcMNPV/ | synXIV | Honeybee melittin | 15%–42% ( | [ |
| vSAt2p+ | As II (sea anemone) | AcMNPV/ | synXIV | 25%–38% ( | [ | |
| vSSh1p+ | Sh I (sea anemone) | AcMNPV/ | synXIV | 35%–42% ( | [ | |
| AaIT | AcMNPV/ | bombyxin | 10% | [ | ||
| vAcTalTX-1 | TalTX-1 (spider) | AcMNPV/ | native | 18%–33% ( | [ | |
| vAcDTX9.2 | DTX9.2 (spider) | AcMNPV/ | 7%–24% ( | [ | ||
| HzEGTp6.9tox34 | TxP-I (inserted in | HzSNPV/ | native | 35% | [ | |
| HzEGThsptox34 | TxP-I (inserted in | HzSNPV/ | native | 32% | [ | |
| HzEGTDA26tox34 | TxP-I (inserted in | HzSNPV/ | DA26 (AcMNPV ORF | native | 39% | [ |
| vV8EE6.9tox34 | TxP-I (inserted in | AcMNPV-V8/ | native | 38% | [ | |
| vV8EEHSPtox34 | TxP-I (inserted in | AcMNPV-V8/ | native | 46% | [ | |
| vhsMAg4p+ | μ-Aga-IV | AcMNPV/ | Honeybee melittin | 20%–71% ( | [ | |
| vhsSAt2p+ | As II | AcMNPV/ | 50%–61% ( | [ | ||
| vDASAt2 | As II (in | AcMNPV/ | synXIV | 37%–40% ( | [ | |
| vDAhsSAt2 | As II (in | AcMNPV/ | 40%–53% ( | [ | ||
| vhsSSh1p+ | Sh I | AcMNPV/ | 45%–55% ( | [ | ||
| vMAg4SAt2 | μ-Aga-IV + As II | AcMNPV/ | synXIV (both toxins) | Honeybee melittin, | 38%–45% ( | [ |
| vhsMAg4SAt2 | μ-Aga-IV + As II | AcMNPV/ | Honeybee melittin, | 43%–57% ( | [ | |
| AcLIT1.p35 | LqhIT1 (scorpion) | AcMNPV/ | native | 16% | [ | |
| AcLIT1.p10 (vAcLqIT1) | LqhIT1 | AcMNPV/ | native | 24%–28% ( | [ | |
| AcLIT2.pol (vAcLqIT2) | LqhIT2 (scorpion) | AcMNPV/ | native | 17%–32% ( | [ | |
| RcHzSNPV (RcHzLqh) | LqhIT2 | HzSNPV/ | bombyxin | 31%–44% ( | [ | |
| AcTOX34.4 | TxP-1 (
| AcMNPV/ | native | Approx. 30%–50% | [ | |
| BmLqhIT2 | LqhIT2 | BmNPV/ | bombyxin | Not estimated | [ | |
| Ro6.9AaIT | AaIT | RoMNPV/ | bombyxin | 19%–37% ( | [ | |
| Ro6.9LqhIT2 | LqhIT2 | RoMNPV/ | bombyxin | 27%–42% ( | [ | |
| AcUW21.AaIT | AaIT | AcMNPV/ | bombyxin | 27% | [ | |
| AcMLF9.AaIT | AaIT | AcMNPV/ | bombyxin | 25%, 26% | [ | |
| AcUW21.LqhIT2 | LqhIT2 | AcMNPV/ | bombyxin | 34% | [ | |
| AcMLF9.LqhIT2 | LqhIT2 | AcMNPV/ | bombyxin | 33%, 34% | [ | |
| HaCXW2 | AaIT (inserted in the | HearSNPV/ | bombyxin | 8%; 13% (relative to | [ | |
| vAcLqIT1-IT2 | LqhIT1 and LqhIT2 | AcMNPV/ | native | 24%, 41% | [ | |
| vAcLqαIT-IT2 | LqhαIT and LqhIT2 | AcMNPV/ | native | 29%, 43% | [ | |
| Ac.LqhIT2(hr5/ie1) | LqhIT2 | AcMNPV/ | native, | Not estimated | [ | |
| Ac.LqhIT2(hr5/39K) | LqhIT2 | AcMNPV/ | bombyxin | Not estimated | [ | |
| Ac.LqhIT2(hr5/lef3) | LqhIT2 | AcMNPV/ | bombyxin | Not estimated | [ | |
| Ac.LqhIT2(hr5/ie1) | LqhIT2 | AcMNPV/ | bombyxin | 37%–56% (n = 10, average 47%) | [ | |
| Ac.AaIT(hr5/ie1) | AaIT | AcMNPV/ | bombyxin | 13%–46% ( | [ | |
| HaSNPV-AaIT | AaIT (inserted in the | HearSNPV/ | Tandem | bombyxin | 4%–27% (relative to | [ |
| Px | Poneratoxin (ant) | AcMNPV/ | none | No improvement | [ | |
| SPx | Poneratoxin | AcMNPV/ | AcMNPV GP67 | 16% | [ | |
| AcIT6 | BotIT6 (scorpion) | AcMNPV/ | AcMNPV EGT | 33% | [ | |
| vAP10IT2 | LqhIT2 | AcMNPV/ | bombyxin | 8%–16% ( | [ | |
| vAPcmIT2 | LqhIT2 | AcMNPV/ | Cytomegalo-virus minimal promoter | bombyxin | 10%–25% ( | [ |
| vAcAaIT.39K | AaIT | AcMNPV/ | bombyxin | 22% | [ | |
| ButaIT-NPV | ButaIT (scorpion) | AcMNPV/ | bombyxin | 43% | [ | |
| P10IT2 | LqhIT2 | AcMNPV/ | bombyxin | 28% | [ | |
| Ppag90IT2 | LqhIT2 | AcMNPV/ | HzNV-1 | bombyxin | 50% | [ |
| AcMNPV-
| AcMNPV/ | native | 13% | [ | ||
| SpltNPV-Δegt-BmK | SpltNPV/ | SpltNPV F protein | 15%; 28% | [ |
AcMNPV, Autographa californica multiple nucleopolyhedrovirus; BmNPV, Bombyx mori nucleopolyhedrovirus; HearSNPV, Helicoverpa armigera single nucleopolyhedrovirus; HzSNPV, Helicoverpa zea single nucleopolyhedrovirus; RoMNPV, Rachiplusia ou multiple nucleopolyhedrovirus; SpltNPV, Spodoptera litura nucleopolyhedrovirus. “TnNPV” could be either AcMNPV or Trichoplusia ni single nucleopolyhedrovirus. Host abbreviations: B. mori, Bombyx mori; G. mellonella, Galleria mellonella; H. armigera, Helicoverpa armigera; H. virescens, Heliothis virescens; H. zea; Helicoverpa zea; O. nubilalis, Ostrinia nubilalis; P. xylostella, Plutella xylostella; S. exigua, Spodoptera exigua; S. frugiperda, Spodoptera frugiperda; S. littoralis, Spodoptera littoralis; S. litura, Spodoptera litura; T. ni, Trichoplusia ni; The percentage by survival time is reduced relative to a control is reported for each bioassay that includes the specified recombinant virus. If results of more than two bioassays are reported, a range of percentages is reported along with the number of bioassays featuring the virus (n) and an average percentage. “No improvement” indicates that survival times achieved with the specified recombinant baculovirus were not lower than the control virus, or there was no statistically significant difference with control virus survival times. “Not estimated” indicates that survival times were not calculated in a way that allowed for a percentage reduction in survival time to be determined; Publications are listed that report the construction of the specified recombinant virus as well as any use of the virus in a bioassay.
Recombinant baculoviruses that express regulators of host physiology.
| Recombinant Baculovirus | Physiological Regulator | Parental Virus/Host Species 1 | Promoter | Signal Peptide | Improvement | Reference 3 |
|---|---|---|---|---|---|---|
| BmDH5 | BmNPV/ | Approximately 20% | [ | |||
| AcRP23.JHE | AcMNPV/ | native | Not determined | [ | ||
| AcUW2(B).JHE (AcJHE) | AcMNPV/ | native | No improvement | [ | ||
| vJHEEGTD | AcMNPV ( | Tandem | native | No improvement relative to | [ | |
| vEHEGTD | AcMNPV ( | Tandem | native | No improvement relative to | [ | |
| AcJHE-SG | AcMNPV/ | native | 16%–31% ( | [ | ||
| AcJHE-HK | AcMNPV/
| native | No improvement | [ | ||
| AcJHE-RH | AcMNPV/
| native | No improvement | [ | ||
| AcJHE-DN | AcMNPV/
| native | No improvement | [ | ||
| vWTPTTHM | AcMNPV/ | Tandem
| No improvement | [ | ||
| vEGT-PTTHM | AcMNPV (
| Tandem
| No improvement | [ | ||
| AcJHE.KK (
| AcMNPV/
| native | 0%–25% ( | [ | ||
| AcMNPV/ | native | No improvement | [ | |||
| AcBX-PBAN | AcMNPV/ | bombyxin | 19%; 26% | [ | ||
| AcJHE-29 | AcMNPV/
| native | No improvement | [ | ||
| AcJHE-524 | AcMNPV/
| native | No improvement | [ | ||
| AcJHE-KSK | AcMNPV/ | native | 17% | [ | ||
| AcJHE-KHK | AcMNPV/ | native | No improvement | [ | ||
| AcHezK-II S | AcMNPV/ | Human placental alkaline phosphatase | Not estimated | [ | ||
| AcHezK-II M | AcMNPV/ | Human placental alkaline phosphatase | Not estimated | [ |
See footnotes for Table 1.
Recombinant baculoviruses that express degradative enzymes.
| Recombinant Baculovirus | Degradative Enzyme | Parental Virus/Host Species 1 | Promoter | Signal Peptide | Improvement
| Reference 3 |
|---|---|---|---|---|---|---|
| vAcMNPV.chi | AcMNPV/ | native | 22%; 23% | [ | ||
| AcIE1TV3.STR1 | Rat stromelysin-1 | AcMNPV/ | native | No improvement | [ | |
| AcMLF9.STR1 | Rat stromelysin-1 | AcMNPV/ | native | No improvement | [ | |
| AcIE1TV3.GEL | Human gelatinase A | AcMNPV/ | native | No improvement | [ | |
| AcMLF9.GEL | Human gelatinase A | AcMNPV/ | native | 12% | [ | |
| AcIE1TV3.ScathL | AcMNPV/ | native | No improvement | [ | ||
| AcMLF9.ScathL | AcMNPV/ | native | 49%; 51% | [ | ||
| AcMNPV-enMP2 | MacoNPV-A enhancin | AcMNPV/ | Native | None | No improvement at same effective dose as control | [ |
| BacVEFPol | TnGV enhancin | AcMNPV/ | None | 17% | [ | |
| AcMLF9.ScathL.CAT | AcMNPV/ | native | 54% | [ | ||
| AcMLF9.ScathL.hsp70/lacZ | AcMNPV/ | native | 51% | [ | ||
| AcBAC–polhvfgf | AcMNPV viral fibroblast growth factor (stimulates protease synthesis/activation) | AcMNPV/ | none | 20%; 23% | [ | |
| AcMNPV-GFP-HCB-Polh | AcMNPV/ | native | 11% | [ | ||
| HearNPV-cathL | HearSNPV/ | Tandem | native | 26%; 26% | [ | |
| vSynScathL | AcMNPV/ | synXIV | native | 26%; 65% | [ | |
| vSynKerat | AcMNPV/ | synXIV | native | 33%; 48% | [ |
See footnotes for Table 1.
Recombinant baculoviruses that express other insecticidal proteins.
| Recombinant Baculovirus | Insecticidal Protein | Parental Virus/Host Species 1 | Promoter | Signal Peptide | Improvement | Reference 3 |
|---|---|---|---|---|---|---|
| Ac(PH+)Bt | AcMNPV/ | none | Not determined | [ | ||
| AcBtm | AcMNPV/ | none | No improvement | [ | ||
| AcBt5 | AcMNPV/ | none | No improvement | [ | ||
| AcBt3 | AcMNPV/ | none | No improvement | [ | ||
| AcBt5/3 | AcMNPV/ | none | No improvement | [ | ||
| BV13T | AcMNPV/ | native | Not estimated | [ | ||
| Bv13.3940 | AcMNPV/ | native | Not estimated | [ | ||
| AcNPV/JM2 | AcMNPV/ | none | No improvement | [ | ||
| AcNPV/FW3 | AcMNPV/ | No improvement | [ | |||
| vHSA50L | PBCV-1 cv-PDG (pyrimidine dimer-specific glycosylase) | AcMNPV/ | none | No improvement | [ | |
| vHSA50LORF | PBCV-1 cv-PDG | AcMNPV/ | none | No improvement | [ | |
| ColorBtrus | AcMNPV polyhedrin- | AcMNPV/ | None | 63% | [ |
See footnotes for Table 1.